Company Overview of Boehringer Ingelheim Limited
Boehringer Ingelheim Limited is engaged in the research, development, and manufacture of prescription medicines, over-the-counter, and animal healthcare products in the United Kingdom. It focuses on various medical conditions, such as respiratory, cardiology, virology, central nervous system, and cerebrovascular. The company offers prescription medicines for the treatment of chronic obstructive pulmonary disease, heart attack, secondary stroke prevention and treatment, high blood pressure, thromboembolic disease, HIV/AIDS, Parkinson's disease, arthritis, and pain relief in cancer. It offers consumer healthcare products in the areas of constipation, antispasmodics, stool softeners, vitamins a...
Bracknell, RG12 8YS
Founded in 1955
Key Executives for Boehringer Ingelheim Limited
Finance & Administration Director
Senior Vice President of Global Biopharma Operations
Head of Established Markets
Compensation as of Fiscal Year 2014.
Boehringer Ingelheim Limited Key Developments
Boehringer Ingelheim Ltd. Wins GBP 431.2 Million Multiple Awardees Contract
Apr 16 15
Boehringer Ingelheim Ltd. won a GBP 431.2 Million multiple awardees contract award from The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health) for the supply of proprietary pharmaceuticals (Contract Award Notice No.: 2015/S 073-128966).
Boehringer Ingelheim Limited Wins GBP 220.9 Million Contract for Supplying Proprietary Pharmaceuticals
Mar 24 15
Boehringer Ingelheim Limited won a GBP 220.9 million (excluding VAT) multiple awardees contract award from The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health) for the supply of proprietary pharmaceuticals (Contract Award Notice No.: 2015/S 057-099494). NHS Framework Agreement for the North of England Pharmacy Purchasing Group for the supply of Proprietary Pharmaceuticals - Tranche A. Period of framework agreement: 1.3.2015 to 28.2.2017 with an option to extend for up to a further 24 months.
Boehringer Ingelheim Announces Phase II Data from its Investigational Compound BI 65506611
Mar 20 15
Boehringer Ingelheim announced Phase II data from its investigational compound BI 65506611. Nearly double the percentage of patients with moderate-to-severe plaque psoriasis achieved clear or almost clear skin (described as PASI 90) after 12 weeks of treatment with BI 655066 compared to ustekinumab (77.1% versus 40% of patients). The study (NCT02054481) investigated the efficacy and safety of the new compound versus the commonly used psoriasis treatment, ustekinumab. BI 655066 had similar safety and tolerability to ustekinumab. The new data were presented in a late-breaker session at the 73rd Annual Meeting of the American Academy of Dermatology in San Francisco, California. In this primary Phase II analysis, the selective IL-23 inhibitor BI 655066 was superior to ustekinumab, an IL-12/23 inhibitor (PASI 90 77.1% vs. 40%). Using sPGA (static Physician Global Assessment) as a secondary outcome measure to determine psoriasis severity, 90% of patients in the study given BI 655066 had clear or almost clear skin compared with 67.5% for ustekinumab. These efficacy analyses were based on pooled dose results for BI 655066 of 90 and 180mg. In addition, results showed that more than double the percentage of psoriasis patients on BI 655066 achieved completely clear skin (PASI 100) after 12 weeks (46% of patients on BI 655066 compared to 17.5% patients on ustekinumab). The most commonly reported side-effects in the trial were a runny nose and sore throat (nasopharyngitis) and headache. In the study, 166 patients were randomly assigned to one of three dose groups of BI 655066 (18, 90 or 180 mg) or ustekinumab (one of two doses according to its label). All study treatments were given as an injection under the skin.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|